Suven Pharma Q3 Outcomes: Internet revenue surges 78% to Rs 83 crore, income up 40%

PE agency Creation backed Suven Pharma web revenue rose 78% year-on-year (YoY) to Rs 83.3 crore in Q3FY25 in comparison with Rs 46.8 crore within the corresponding interval of the earlier yr.

Income grew 40% YoY to Rs 307.2 crore in Q3FY25 pushed by doubling of CDMO enterprise pushed by R&D and enterprise improvement efforts.

Gross margins for the quarter stood at 71.5% and adjusted EBITDA margins stood at 38.7%.

The Hyderabad-based firm mentioned it’s seeing sturdy demand throughout levels on the again of secular macro tailwinds.
It mentioned two molecules added this quarter wherein one molecule superior to Part 3 and one instantly added to Part III (laterals addition), rising whole energetic Part 3 initiatives to fifteen with 9 molecules.

It additionally mentioned a beforehand highlighted constructive readout on Part III molecule has now met the first endpoint for a second indication and onboarded a brand new strategic buyer – one of many high 5 international pharma leaders for early-to-mid-phase initiatives.

“We proceed to make enterprise improvement efforts and stay targeted on high-value CDMO choices and growth in area of interest know-how platforms in step with our strategic imaginative and prescient,’ mentioned Vivek Sharma, government chairman.”Our investments in ADCs and oligonucleotides with quick underlying market development place us nicely for sustained mid and long-term development,” Sharma added.